362 related articles for article (PubMed ID: 23376850)
41. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
[TBL] [Abstract][Full Text] [Related]
42. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
43. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
44. Cell-targeting fusion constructs containing recombinant gelonin.
Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
[TBL] [Abstract][Full Text] [Related]
45. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
Ríos-Luci C; García-Alonso S; Díaz-Rodríguez E; Nadal-Serrano M; Arribas J; Ocaña A; Pandiella A
Cancer Res; 2017 Sep; 77(17):4639-4651. PubMed ID: 28687619
[TBL] [Abstract][Full Text] [Related]
46. Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.
Chen P; Bordeau BM; Zhang Y; Balthasar JP
Mol Cancer Ther; 2022 Oct; 21(10):1573-1582. PubMed ID: 35930739
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins.
Goleij Z; Mahmoodzadeh Hosseini H; Sedighian H; Behzadi E; Halabian R; Sorouri R; Imani Fooladi AA
J Steroid Biochem Mol Biol; 2020 Jun; 200():105651. PubMed ID: 32147458
[TBL] [Abstract][Full Text] [Related]
48. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
[TBL] [Abstract][Full Text] [Related]
49. Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence.
Berstad MB; Weyergang A; Berg K
Biochim Biophys Acta; 2012 Dec; 1820(12):1849-58. PubMed ID: 22981913
[TBL] [Abstract][Full Text] [Related]
50. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
51. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
52. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.
Lane HA; Motoyama AB; Beuvink I; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S21-2. PubMed ID: 11521716
[TBL] [Abstract][Full Text] [Related]
53. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
[TBL] [Abstract][Full Text] [Related]
54. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
[TBL] [Abstract][Full Text] [Related]
55. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
Inoue S; Ding H; Portilla-Arias J; Hu J; Konda B; Fujita M; Espinoza A; Suhane S; Riley M; Gates M; Patil R; Penichet ML; Ljubimov AV; Black KL; Holler E; Ljubimova JY
Cancer Res; 2011 Feb; 71(4):1454-64. PubMed ID: 21303974
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
57. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
58. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
59. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
60. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]